small molecule

RECARBRIO

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Loss of exclusivityMarch 2033latest FDA-listed patent expiry

CompanyMERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC

Drug detail

Brand name	RECARBRIO
Active ingredient	CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Strength	EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	July 2019
Marketing status	RX

Listed patents

Patent	Expires	Type
8487093	March 2033	substance, product

Regulatory exclusivity

Code	Expires
GAIN	July 2029
NPP	December 2028
NCE	July 2024

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC